Form 4: Fulgent Genetics CSO Sells Shares for Tax Obligations

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 548 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of 548 shares of common stock.
• The transaction occurred on August 25, 2025, at a weighted-average price of $21.5016 per share.
• The sale was conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units that were granted on February 23, 2023.
• Following this transaction, Mr. Gao beneficially owns 959,091 shares of Fulgent Genetics common stock.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating a pre-arranged sale.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale for tax purposes, which is generally neutral to slightly negative due to reduced insider ownership, but not indicative of a negative outlook on the company. The pre-planned nature under Rule 10b5-1 mitigates any negative sentiment.

Positives

• The sale was for tax withholding obligations, which is a common and often pre-planned event for executives receiving equity compensation.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged sale not based on inside information.
• Mr. Gao retains a significant beneficial ownership of 959,091 shares, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even for tax purposes, reduces the direct ownership stake of a key executive.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports a past insider transaction.

Industry Context

This filing reports a routine insider transaction, which is a common occurrence across all publicly traded companies when executives receive equity compensation and sell shares to cover tax obligations. It does not provide specific insights into broader industry trends for the genetics or healthcare sectors.

Related Party Transactions

• The reported transaction is an insider sale of common stock by the Chief Scientific Officer, Hanlin Gao, to satisfy tax withholding obligations related to vested restricted stock units.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in direct insider ownership, but the reason (tax withholding) is common and generally not a cause for concern. The executive retains a substantial stake.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Recommendation

This Form 4 reports a routine insider sale by the Chief Scientific Officer to cover tax obligations from vested restricted stock units. Such transactions are common and pre-planned under Rule 10b5-1, and do not typically signal a change in the company's fundamental outlook or the insider's confidence. The executive retains a substantial stake in the company. Therefore, the filing itself does not provide a basis for a 'buy' or 'sell' recommendation, maintaining a 'hold' position based solely on this information.

Keywords

Fulgent Genetics, FLGT, Insider Trading, Form 4, Stock Sale, Hanlin Gao, Chief Scientific Officer, Restricted Stock Units, Tax Withholding, 10b5-1 Plan